ALAMEDA, CA, September 17, 2015 (Business Wire) – Penumbra, Inc., today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $30.00 per share. The offering is scheduled to close on September 23, 2015, subject to customary closing conditions. The underwriters for the offering will also have a 30-day option to purchase up to an additional 600,000 shares of Penumbra’s common stock at the price to the public, less the underwriting discounts and commissions.
Penumbra’s common stock is expected to begin trading on the New York Stock Exchange on September 18, 2015, under the symbol “PEN”. J.P Morgan and BofA Merrill Lynch are acting as joint lead book-running managers for the offering. Wells Fargo Securities and Canaccord Genuity are acting as co-managers for the offering. Perella Weinberg Partners is acting as independent capital markets advisor to Penumbra for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 17, 2015. The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY 11717, (tel: +1 866 803 9204); or BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Penumbra, Inc., headquartered in Alameda, California is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical needs across two major markets, neuro and peripheral vascular. Penumbra has approximately 1,000 employees and sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets. Penumbra and the Penumbra logo are trademarks of Penumbra, Inc.
Head of Investor Relations
Source: Penumbra, Inc.